PDCD1 and cancer: The confirmation of IPRES co-enrichment in other independent tumor such as pancreatic adenocarcinoma indicates a transcriptomic program among different type of cancers and it may be a new way to enhance the efficacy of PD-1/PD-L1 blockade by inhibit the IPRES relevant biological processes.